Literature DB >> 12557126

HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.

L F Barcellos1, J R Oksenberg, A B Begovich, E R Martin, S Schmidt, E Vittinghoff, D S Goodin, D Pelletier, R R Lincoln, P Bucher, A Swerdlin, M A Pericak-Vance, J L Haines, S L Hauser.   

Abstract

Models of disease susceptibility in multiple sclerosis (MS) often assume a dominant action for the HLA-DRB1*1501 allele and its associated haplotype (DRB1*1501-DQB1*0602 or DR2). A robust and phenotypically well-characterized MS data set was used to explore this model in more detail. A dose effect of HLA-DR2 haplotypes on MS susceptibility was revealed. This observation suggests that, in addition to the role of HLA-DR2 in MS, two copies of a susceptibility haplotype further increase disease risk. Second, we report that DR2 haplotypes modify disease expression. There is a paucity of benign MS and an increase of severe MS in individuals homozygous for DR2. Concepts of the molecular mechanisms that underlie linkage and association of the human leukocyte antigen (HLA) region to MS need to be revised to accommodate these data.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12557126      PMCID: PMC1180245          DOI: 10.1086/367781

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  43 in total

1.  Correcting for a potential bias in the pedigree disequilibrium test.

Authors:  E R Martin; M P Bass; N L Kaplan
Journal:  Am J Hum Genet       Date:  2001-04       Impact factor: 11.025

Review 2.  Identifying disease modifying genes in multiple sclerosis.

Authors:  Orhun H Kantarci; Mariza de Andrade; Brian G Weinshenker
Journal:  J Neuroimmunol       Date:  2002-02       Impact factor: 3.478

3.  Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals.

Authors:  M V Tejada-Simon; J Hong; V M Rivera; J Z Zhang
Journal:  Eur J Immunol       Date:  2001-03       Impact factor: 5.532

4.  CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group.

Authors:  L F Barcellos; A M Schito; J B Rimmler; E Vittinghoff; A Shih; R Lincoln; S Callier; M K Elkins; D E Goodkin; J L Haines; M A Pericak-Vance; S L Hauser; J R Oksenberg
Journal:  Immunogenetics       Date:  2000-04       Impact factor: 2.846

5.  Association of HLA alleles and clinical features in patients with synovitis of recent onset.

Authors:  H S El-Gabalawy; R Goldbach-Mansky; D Smith; T Arayssi; S Bale; P Gulko; C Yarboro; R L Wilder; J H Klippel; H R Schumacher
Journal:  Arthritis Rheum       Date:  1999-08

6.  Additive effect of the HLA-DR15 haplotype on susceptibility to multiple sclerosis.

Authors:  H B Rasmussen; M A Kelly; J Clausen
Journal:  Mult Scler       Date:  2001-04       Impact factor: 6.312

7.  Evidence of linkage with HLA-DR in DRB1*15-negative families with multiple sclerosis.

Authors:  A Ligers; D A Dyment; C J Willer; A D Sadovnick; G Ebers; N Risch; J Hillert
Journal:  Am J Hum Genet       Date:  2001-08-22       Impact factor: 11.025

8.  Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis.

Authors:  Justin P Rubio; Melanie Bahlo; Helmut Butzkueven; Ingrid A F van Der Mei; Michèle M Sale; Joanne L Dickinson; Patricia Groom; Laura J Johnson; Rex D Simmons; Brian Tait; Mike Varney; Bruce Taylor; Terence Dwyer; Robert Williamson; Nicholas M Gough; Trevor J Kilpatrick; Terence P Speed; Simon J Foote
Journal:  Am J Hum Genet       Date:  2002-03-29       Impact factor: 11.025

Review 9.  HLA association with autoimmune disease: a failure to protect?

Authors:  E Zanelli; F C Breedveld; R R de Vries
Journal:  Rheumatology (Oxford)       Date:  2000-10       Impact factor: 7.580

10.  Genetic basis for clinical expression in multiple sclerosis.

Authors:  L F Barcellos; J R Oksenberg; A J Green; P Bucher; J B Rimmler; S Schmidt; M E Garcia; R R Lincoln; M A Pericak-Vance; J L Haines; S L Hauser
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

View more
  75 in total

Review 1.  Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice.

Authors:  David Luckey; Dikshya Bastakoty; Ashutosh K Mangalam
Journal:  J Autoimmun       Date:  2011-05-31       Impact factor: 7.094

2.  Modes of action of HLA-DR susceptibility specificities in multiple sclerosis.

Authors:  Helena Modin; Wiveka Olsson; Jan Hillert; Thomas Masterman
Journal:  Am J Hum Genet       Date:  2004-06       Impact factor: 11.025

3.  Inheritance mode of multiple sclerosis: the effect of HLA class II alleles is stronger than additive.

Authors:  Maartje Boon; Ilja M Nolte; Jacques De Keyser; Charles H C M Buys; Gerard J te Meerman
Journal:  Hum Genet       Date:  2004-09       Impact factor: 4.132

4.  Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis.

Authors:  Justin P Rubio; Melanie Bahlo; Niall Tubridy; Jim Stankovich; Rachel Burfoot; Helmut Butzkueven; Caron Chapman; Laura Johnson; Mark Marriott; Grant Mraz; Brian Tait; Chris Wilkinson; Bruce Taylor; Terence P Speed; Simon J Foote; Trevor J Kilpatrick
Journal:  Hum Genet       Date:  2004-03-11       Impact factor: 4.132

Review 5.  Multiple sclerosis genetics--is the glass half full, or half empty?

Authors:  Jorge R Oksenberg; Sergio E Baranzini
Journal:  Nat Rev Neurol       Date:  2010-07-13       Impact factor: 42.937

6.  A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms.

Authors:  Marcos M Miretti; Emily C Walsh; Xiayi Ke; Marcos Delgado; Mark Griffiths; Sarah Hunt; Jonathan Morrison; Pamela Whittaker; Eric S Lander; Lon R Cardon; David R Bentley; John D Rioux; Stephan Beck; Panos Deloukas
Journal:  Am J Hum Genet       Date:  2005-03-01       Impact factor: 11.025

7.  Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype.

Authors:  Mireia Sospedra; Paolo A Muraro; Irena Stefanová; Yingdong Zhao; Katherine Chung; Yili Li; Marc Giulianotti; Richard Simon; Roy Mariuzza; Clemencia Pinilla; Roland Martin
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

8.  An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus.

Authors:  G C DeLuca; S V Ramagopalan; B M Herrera; D A Dyment; M R Lincoln; A Montpetit; M Pugliatti; M C N Barnardo; N J Risch; A D Sadovnick; M Chao; S Sotgiu; T J Hudson; G C Ebers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

9.  Methods for high-density admixture mapping of disease genes.

Authors:  Nick Patterson; Neil Hattangadi; Barton Lane; Kirk E Lohmueller; David A Hafler; Jorge R Oksenberg; Stephen L Hauser; Michael W Smith; Stephen J O'Brien; David Altshuler; Mark J Daly; David Reich
Journal:  Am J Hum Genet       Date:  2004-04-14       Impact factor: 11.025

Review 10.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.